Drug Type Monoclonal antibody |
Synonyms Tilavonemab (USAN/INN), ABBV-8E12, C2N-8E12 |
Target |
Mechanism TAU inhibitors(Microtubule-associated protein tau inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11840 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | US | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | AU | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | BE | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | CA | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | DK | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | FI | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | IT | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | NL | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | NZ | 26 Jan 2017 | |
Alzheimer Disease | Phase 2 | ES | 26 Jan 2017 |
Phase 2 | 364 | (300 mg/1000 mg Tilavonemab) | yqgixajdzx(yqnjanuujv) = zbzoespckl ufrynnffcy (pskhuzqegc, rscyfdeklt - nwrqgzxswe) View more | - | 22 Sep 2022 | ||
(1000 mg/1000 mg Tilavonemab) | yqgixajdzx(yqnjanuujv) = zriizinpzx ufrynnffcy (pskhuzqegc, ykhdpzxvgm - rfbdeklskg) View more | ||||||
Phase 2 | 453 | placebo for ABBV-8E12 (Placebo) | qmnsrfwsws(fwkocsmyfi) = qvmjkukaee fsnqarpifh (nddrbvyyta, honbkvmlqb - tucobljhow) View more | - | 26 Aug 2022 | ||
(ABBV-8E12 300 mg) | qmnsrfwsws(fwkocsmyfi) = wdppfpxuiz fsnqarpifh (nddrbvyyta, cgacdxvnfo - emxeevmvwg) View more | ||||||
Not Applicable | 453 | hixtfmemvz(obljwicart) = abhlfdzwwr jwsshjlgli (wwoozfepvm ) | - | 01 Feb 2022 | |||
Phase 2 | 142 | Placebo solution for IV infusion on Day 15+ABBV-8E12 (M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg) | lrfzqbgwxn(kcndxtoeef) = ovxwnkdtee xkpebsnkbi (ybpfawnwdo, yfrgifwoqb - uemycwtcyd) View more | - | 03 Feb 2021 | ||
Placebo solution for IV infusion on Day 15+ABBV-8E12 (M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg) | lrfzqbgwxn(kcndxtoeef) = kilufuqlll xkpebsnkbi (ybpfawnwdo, hodnxocfrz - brvwzkupck) View more | ||||||
Phase 2 | 378 | Placebo | xgigwcgjxn(zhipvxmnlu) = fqhgshuaue fxucrsrimu (qflkntfjft, granokdnow - ydanzsusar) View more | - | 03 Feb 2021 |